A Phase 3 interventional study of Evolocumab Pre-filled Syringe and Evolocumab AI/pen in Primary Hypercholesterolemia and Mixed Dyslipidemia, sponsored by Amgen. Completed at 26 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-11-29.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.
Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 26th largest by enrollment, is one of 11 that started in 2013, is one of 22 in phase 3, and was the 15th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 24 · Phase 4 7
First in 2011; this study’s year is marked. 11 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 149 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 308 across the 36 interventional studies. Of the 32 that completed or were terminated, 31 (97%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 36 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
35 studies in Hypercholesterolemia by Amgen: 1 open now, 1 under way, none of them phase 3. Of 34 finished, 30 (88%) have results posted.
Among the 35 studies in Hypercholesterolemia by Amgen, this one is the 26th largest by enrollment of the 31 interventional ones that give a count, is one of 11 that started in 2013, is one of 22 in phase 3, and was the 15th registered.
Amgen’s Hypercholesterolemia studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 36 studies testing evolocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 35 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to assess users' ability to administer a full dose of evolocumab in home-use using either a pre-filled syringe or autoinjector/pen.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received evolocumab 140 mg every 2 weeks for 4 weeks (Day 1, Week 2, and Week 4) subcutaneously using a prefilled syringe (PFS). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 2 and 4.
Biological: Evolocumab Pre-filled Syringe
Participants received evolocumab 140 mg every 2 weeks for 4 weeks (Day 1, Week 2, and Week 4) subcutaneously using a prefilled autoinjector/pen (AI/pen). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 2 and 4.
Biological: Evolocumab AI/pen
Evolocumab subcutaneous injection via a single use, disposable pre-filled syringe.
Also known as: AMG 145, Repatha
Drug page: Evolocumab
Evolocumab subcutaneous injection via a handheld mechanical (spring-based) autoinjector/pen.
Also known as: AMG 145, Repatha
Percentage of Participants With Full Administration of Evolocumab at Both Weeks 2 and 4
Self-administration of evolocumab was assessed by a telephone interview at Weeks 2 and 4. Each participant was asked about all attempted injection(s) and if the injection was administered in part, full, or none at all.
Time frame: Week 2 and Week 4
Percent Change From Baseline in LDL-C at Week 6
Time frame: Baseline and Week 6
Eligible patients were men and women ≥ 18 and ≤ 80 years of age with fasting low-density lipoprotein cholesterol (LDL-C) ≥ 85 mg/dL, fasting triglycerides ≤ 400 mg/dL and on a stable dose of a statin with or without ezetimibe for at least 4 weeks. The first patient enrolled on 18 April 2013 and last patient enrolled on 05 August 2013.
| Milestone | Evolocumab PFS | Evolocumab AI/Pen |
|---|---|---|
| Started | 75 | 74 |
| Received treatment | 75 | 74 |
| Completed | 74 | 70 |
| Not completed | 1 | 4 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Sponsor decision | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
Self-administration of evolocumab was assessed by a telephone interview at Weeks 2 and 4. Each participant was asked about all attempted injection(s) and if the injection was administered in part, full, or none at all.
| percentage of participants | Evolocumab PFS | Evolocumab AI/Pen |
|---|---|---|
| Percentage of Participants With Full Administration of Evolocumab at Both Weeks 2 and 4 | 96.0 (88.9 to 98.6) | 89.2 (80.1 to 94.4) |
| percent change | Evolocumab PFS | Evolocumab AI/Pen |
|---|---|---|
| Percent Change From Baseline in LDL-C at Week 6 | -59.74 ± 2.57 | -63.43 ± 2.67 |
Collected over From first dose of study drug until 28 days after last study drug administration (up to 8 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Evolocumab PFS | — | 3/75 (4%) | 4/75 (5.3%) |
| Evolocumab AI/Pen | — | 2/74 (2.7%) | 2/74 (2.7%) |
| Event | Evolocumab PFS | Evolocumab AI/Pen |
|---|---|---|
| Cerebrovascular accidentNervous system disorders | 0/75 | 1/74 |
| Glomerulonephritis minimal lesionRenal and urinary disorders | 0/75 | 1/74 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/75 | 0/74 |
| CholecystitisHepatobiliary disorders | 1/75 | 0/74 |
| CholelithiasisHepatobiliary disorders | 1/75 | 0/74 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/75 | 0/74 |
| Event | Evolocumab PFS | Evolocumab AI/Pen |
|---|---|---|
| HeadacheNervous system disorders | 4/75 | 2/74 |
Full analysis set (all randomized participants who received at least 1 dose of study drug).
| Age, Continuous(years) | Evolocumab PFS | Evolocumab AI/Pen | Total |
|---|---|---|---|
| Mean | 61.2 ± 11.1 | 60.6 ± 9.6 | 60.9 ± 10.3 |
| Sex: Female, Male(Participants) | Evolocumab PFS | Evolocumab AI/Pen | Total |
|---|---|---|---|
| Female | 36 | 26 | 62 |
| Male | 39 | 48 | 87 |
| Race/Ethnicity, Customized(participants) | Evolocumab PFS | Evolocumab AI/Pen | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 7 | 9 |
| Black or African American | 11 | 7 | 18 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| White | 62 | 58 | 120 |
| Missing | 0 | 1 | 1 |
| Race/Ethnicity, Customized(participants) | Evolocumab PFS | Evolocumab AI/Pen | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 6 | 15 |
| Not Hispanic or Latino | 66 | 68 | 134 |
| Stratification Factor: LDL-C Level(participants) | Evolocumab PFS | Evolocumab AI/Pen | Total |
|---|---|---|---|
| < 130 mg/dL | 56 | 56 | 112 |
| ≥ 130 mg/dL | 19 | 18 | 37 |
| LDL-C Concentration(mg/dL) | Evolocumab PFS | Evolocumab AI/Pen | Total |
|---|---|---|---|
| Mean | 116.9 ± 25.0 | 118.1 ± 28.7 | 117.5 ± 26.8 |
Ran from Apr 2013 to primary completion in Sep 2013, 4 months.
Results were first posted in Oct 2015, 2 years 1 month after primary completion. A results delay was requested in May 2014.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 4 months is below that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab